A Phase I/II Single-Arm, Open-Label, Exploratory Study Evaluating the Safety and Efficacy of Stereotactic Body Radiotherapy (SBRT) Combined With Gemcitabine and Iparomlimab-Toripalimab in Borderline Resectable Pancreatic Cancer (TJSPAC-03)
A Phase I/II Single-Arm, Open-Label, Exploratory Study Evaluating the Safety and Efficacy of Concurrent Stereotactic Body Radiotherapy (SBRT) Combined With Gemcitabine and Iparomlimab-Toripalimab in Borderline Resectable Pancreatic Cancer (TJSPAC-03)
This is a Phase I/II, single-arm, open-label, exploratory study aimed at evaluating the safety, tolerability, and preliminary efficacy of stereotactic body radiotherapy (SBRT) combined with gemcitabine and iparomlimab-toripalimab in patients with borderline resectable pancreatic cancer. The study is divided into two phases: The Phase Ib dose-escalation phase will use a "3+3" design to explore the maximum tolerated dose (MTD) of SBRT (6 Gy×5 F, 7 Gy×5 F, 8 Gy×5 F) combined with gemcitabine and iparomlimab-toripalimab. The Phase II phase will further evaluate the efficacy and safety of this combination regimen based on the SBRT dose determined in Phase Ib. The primary efficacy endpoint is the R0 resection rate.
研究概览
地位
详细说明
This is a single-center, Phase I/II, single-arm, open-label, exploratory clinical study initiated by Tianjin Medical University Cancer Institute & Hospital.
Phase Ib (Dose-Escalation Phase): A classic "3+3" design will be used to explore the dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) of SBRT. Three pre-specified SBRT dose levels are planned: 6 Gy×5 F, 7 Gy×5 F, and 8 Gy×5 F. All subjects will concurrently receive standard-dose gemcitabine chemotherapy and iparomlimab-toripalimab immunotherapy. The DLT observation period is 6 months from the start of treatment, focusing on Grade 3 or higher SBRT-related toxicities in organs at risk. The MTD is defined as the highest dose level at which ≤33% (i.e., no more than 1 out of 6) of subjects experience a DLT during the observation period.
Phase II (Expansion Phase): Based on the SBRT MTD determined in Phase Ib, preoperative neoadjuvant therapy will be administered in combination with gemcitabine and iparomlimab-toripalimab. The treatment cycle consists of 3 cycles, expected to last 12 weeks. Tumor assessment will be performed after 2 cycles of treatment. If there is no disease progression and adverse reactions are tolerable, treatment will continue. Surgical resection will be performed 3-4 weeks after the last dose of chemotherapy and immunotherapy. Postoperatively, if the investigator determines the patient may benefit, adjuvant therapy will be administered, consisting of 4 cycles of gemcitabine chemotherapy and maintenance immunotherapy with iparomlimab-toripalimab for up to 1 year. The primary endpoint is the R0 resection rate.
研究类型
注册 (估计的)
阶段
- 阶段2
- 阶段1
联系人和位置
学习联系方式
- 姓名:Maobin Meng(Co-Principal Investigator), PhD
- 电话号码:15202231270
- 邮箱:mmeng@tmu.edu.cn
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Age ≥18 years and ≤75 years, both genders.
- Histologically or cytologically confirmed pancreatic ductal adenocarcinoma.
- Radiographically assessed as borderline resectable pancreatic cancer according to NCCN guidelines.
- At least one measurable lesion per RECIST v1.1 criteria.
- Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.
- Adequate organ and bone marrow function.
- Expected survival ≥ 6 months.
- Voluntarily signed informed consent form.
Exclusion Criteria:
- Known distant metastases.
- Prior systemic anti-tumor therapy or radiotherapy for pancreatic cancer.
- Active autoimmune disease requiring systemic treatment within the past 2 years.
- History of other malignancies within the past 5 years, except for cured carcinoma in situ of the cervix, non-melanoma skin cancer, or superficial bladder tumor.
- Uncontrolled comorbid conditions, including but not limited to active infections, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia.
- Pregnant or lactating women.
- Any condition that, in the investigator's opinion, would make the subject unsuitable for participation in the study.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Iparomlimab-Tuvonralimab + Gemcitabine Group
Participants will receive Iparomlimab-Tuvonralimab (10 mg/kg, IV, D1) combined with Gemcitabine (1000 mg/m², IV, D1 and D8) every 3 weeks for up to 6 cycles. After 6 cycles, participants without disease progression and with acceptable tolerance may continue to receive Iparomlimab-Tuvonralimab (10 mg/kg, IV, D1, every 3 weeks) as maintenance therapy until disease progression, unacceptable toxicity, withdrawal of consent, loss to follow-up, death, or study termination. |
Iparomlimab/Tuvonralimab (Code: QL1706) is a bispecific antibody targeting PD-1 and CTLA-4. It is administered by intravenous infusion at a dose of XX mg/kg once every 3 weeks until disease progression or unacceptable toxicity. Gemcitabine (Brand name: Gemzar) is a nucleoside analogue chemotherapeutic agent. It is administered by intravenous infusion at a dose of 1000 mg/m² on Days 1 and 8 of each 21-day cycle until disease progression or unacceptable toxicity. SBRT is a highly precise form of radiation therapy that delivers high doses of radiation to the tumor while minimizing exposure to surrounding healthy tissues. It is administered in XX fractions over XX days/weeks. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Objective Response Rate, ORR
大体时间:From first dose to disease progression or study completion, up to approximately 24 months
|
Objective Response Rate assessed by RECIST v1.1, defined as the proportion of participants who achieve complete response (CR) or partial response (PR). |
From first dose to disease progression or study completion, up to approximately 24 months
|
|
Incidence of Adverse Events
大体时间:From first dose to 90 days after last dose, up to approximately 27 months
|
Incidence and severity of adverse events assessed by CTCAE v5.0, including treatment-related adverse events (TRAEs), serious adverse events (SAEs), and immune-related adverse events (irAEs). |
From first dose to 90 days after last dose, up to approximately 27 months
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Disease Control Rate, DCR
大体时间:From first dose to disease progression or study completion, up to approximately 24 months
|
Disease Control Rate assessed by RECIST v1.1, defined as the proportion of participants who achieve complete response (CR), partial response (PR), or stable disease (SD). |
From first dose to disease progression or study completion, up to approximately 24 months
|
|
Progression-Free Survival, PFS
大体时间:From first dose to disease progression or death, up to approximately 24 months
|
Progression-Free Survival assessed by RECIST v1.1, defined as the time from first dose to the first documentation of disease progression or death from any cause. |
From first dose to disease progression or death, up to approximately 24 months
|
|
Overall Survival, OS
大体时间:From first dose to death or last follow-up, up to approximately 36 months
|
Defined as the time from first dose to death from any cause. |
From first dose to death or last follow-up, up to approximately 36 months
|
|
Duration of Response, DOR
大体时间:From first documentation of response to disease progression or death, up to approximately 24 months
|
Duration of Response assessed by RECIST v1.1, defined as the time from the first documentation of complete response (CR) or partial response (PR) to the first documentation of disease progression or death from any cause. |
From first documentation of response to disease progression or death, up to approximately 24 months
|
其他结果措施
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Correlation between Biomarkers and Clinical Efficacy
大体时间:From first dose to study completion, up to approximately 36 months
|
To explore the correlation between biomarkers such as PD-L1 expression, tumor mutational burden (TMB), microsatellite instability (MSI) status in tumor tissue and clinical efficacy endpoints including ORR, PFS, and OS. |
From first dose to study completion, up to approximately 36 months
|
|
Quality of Life Assessment
大体时间:From baseline to 90 days after last dose, up to approximately 27 months
|
To evaluate changes in quality of life during and after treatment using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30). |
From baseline to 90 days after last dose, up to approximately 27 months
|
|
Dynamic Changes of Peripheral Blood Immune Cell Subsets and Cytokines
大体时间:From first dose to disease progression or study completion, up to approximately 24 months
|
To explore the dynamic changes of peripheral blood immune cell subsets (CD3+, CD4+, CD8+ T cells, etc.) and cytokines (IL-6, TNF-α, IFN-γ, etc.) during treatment and their correlation with efficacy and adverse events. |
From first dose to disease progression or study completion, up to approximately 24 months
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- TJSPAC-03
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
This is a prospective, single-arm, single-center Phase II clinical study to evaluate the efficacy and safety of Iparomlimab/Tuvonralimab combined with gemcitabine in the treatment of locally advanced pancreatic cancer. The study plans to enroll 30 patients with histologically or cytologically confirmed locally advanced pancreatic ductal adenocarcinoma. Subjects will receive Iparomlimab/Tuvonralimab combined with gemcitabine until disease progression, intolerable toxicity, withdrawal of informed consent, or completion of 6 cycles of treatment. The primary endpoint is objective response rate (ORR), and secondary endpoints include progression-free survival (PFS), overall survival (OS), disease control rate (DCR), and safety.
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.